3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist

The article highlights strong operating momentum across three biotech names, led by Krystal Biotech’s 2024 revenue of $389.1 million (+34% YoY) and EPS of $6.84 (+128% YoY), and Madrigal’s 2025 revenue of $958.4 million (+432% YoY) driven by Rezdiffra. Exelixis remains a durable oncology franchise with Cabometyx, while pipeline assets like zanzalintinib could extend growth before generic pressure arrives in the early 2030s. Overall, the piece is constructive on the companies’ commercial and clinical outlooks but is more opinion-driven than event-driven.

Analysis

This is a small-cap biotech setup where the market is likely still underpricing duration of cash flows relative to the perceived single-product risk. The common thread is not just “good launches,” but the conversion of regulatory first-mover advantage into commercial inertia: once a drug becomes the default specialist-prescribed option in a niche, share gains can persist for years even before label expansion. That makes the real winners less the headline launch and more the downstream effects on physician habit formation, payer contracting, and pipeline optionality.

The main second-order opportunity is the diffusion effect: if these launches validate screening and diagnosis pathways, the addressable market can expand faster than the article implies. For KRYS and MDGL, the bottleneck is not science alone but patient identification and specialist throughput; that means commercial spend can produce nonlinear returns if awareness remains underpenetrated. For EXEL, the market may be too focused on cabometyx’s eventual LOE and not enough on whether zanzalintinib can extend the franchise through combination therapy before patent decay becomes an issue.

The key risks are binary and timing-sensitive. MDGL carries the harshest regulatory convexity because accelerated approval can re-rate quickly if confirmatory data disappoints; that risk is more of a 6-18 month catalyst than an immediate one. KRYS and EXEL look more durable, but both are vulnerable to valuation compression if growth slows even modestly, since the market is likely paying up for continuity rather than current earnings power.

Consensus appears to be underweighting how much of the upside comes from pipeline optionality, not just the current products. The more interesting trade is not outright long every name, but separating de-risked commercial execution from regulatory overhangs and maturity risk. In this cohort, the asymmetry is best where revenue is already inflecting and future indications can extend the franchise without requiring a wholly new commercial build.

Key Decisions for Investors

• Long KRYS on any post-rally pullback over the next 2-4 weeks; best risk/reward is owning a de-risked commercial story with additional region expansion and pipeline optionality. Use a 10-15% trailing stop because the main risk is valuation compression, not operational failure.
• Maintain a tactical long MDGL only as a catalyst trade into confirmatory-data windows over the next 6-12 months; size smaller than KRYS/EXEL due to accelerated-approval binary risk. Consider call spreads rather than equity to define downside.
• Long EXEL as a relative-value “durability” name versus higher-beta oncology peers for a 6-18 month horizon. The market should reward franchise extension potential ahead of LOE; downside is limited unless zanzalintinib stumbles, but upside may be slower than KRYS/MDGL.
• Pair trade: long KRYS / short a basket of pre-commercial biotech names with no approved product. The thesis is that commercialized rare-disease assets deserve a premium when execution is visible and cash generation reduces financing risk.
• Avoid chasing MDGL after sharp run-ups; if holding, hedge with short-dated put spreads around regulatory milestones. The asymmetry flips quickly if confirmatory trial visibility worsens, making this the cleanest hedgeable catalyst risk in the group.